KeraNetics, Inc.

KeraNetics, Inc. is a medical device company founded in 2008 in Winston-Salem, North Carolina, specializing in keratin-based topical treatments for radiation-induced skin injury. The company's flagship product is KeraStat® Cream, an FDA-cleared prescription topical cream designed for the management of radiation dermatitis in patients undergoing radiotherapy for head, neck, throat, skin, and breast cancers. Radiation dermatitis affects an estimated 95% of the 4 million Americans receiving radiation therapy annually, presenting with symptoms including erythema, soreness, pigmentation changes, pruritus, desquamation, blistering, ulceration, and necrosis. KeraStat® Cream harnesses keratin proteins to provide symptomatic management and is indicated for both prophylactic (preventative) use following the first radiation dose and therapeutic management of established radiation burns. The product is available in two formulations: a 1-ounce tube for radiation dermatitis and a 5-milliliter tube for general wound care. KeraStat® is a prescription product processed through major electronic medical record systems such as Epic and distributed via specialty pharmacies including ASPN Pharmacies. The company has received significant federal recognition, including a $3.5 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for cutaneous radiation injury management. KeraNetics' origins trace to partnerships with the Wake Forest Institute for Regenerative Medicine and include experience addressing battlefield traumatic injuries, reflecting a clinical focus on regenerative wound care solutions.